Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up – Time to Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $45.66, but opened at $47.62. Definium Therapeutics shares last traded at $46.43, with a volume of 706,068 shares.

Analysts Set New Price Targets

DFTX has been the topic of several research reports. Needham & Company LLC raised their price objective on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, June 23rd. Robert W. Baird increased their target price on Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Leerink Partners set a $52.00 price target on Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Finally, Oppenheimer set a $60.00 price objective on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $49.23.

Definium Therapeutics Trading Up 0.4%

The stock has a market capitalization of $4.42 billion, a P/E ratio of -17.79 and a beta of 2.20. The stock’s fifty day moving average price is $31.43 and its two-hundred day moving average price is $22.77. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Equities research analysts forecast that Definium Therapeutics, Inc. will post -2.27 EPS for the current year.

Insider Buying and Selling at Definium Therapeutics

In other news, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the transaction, the chief executive officer owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. This represents a 2.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 48,096 shares of company stock valued at $2,165,763. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DFTX. Sender Co & Partners Inc. bought a new stake in Definium Therapeutics during the 3rd quarter valued at $305,000. Scientech Research LLC purchased a new position in shares of Definium Therapeutics in the third quarter valued at about $286,000. Mercer Global Advisors Inc. ADV increased its position in shares of Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares during the period. BNP Paribas Financial Markets increased its position in shares of Definium Therapeutics by 82.0% in the third quarter. BNP Paribas Financial Markets now owns 15,320 shares of the company’s stock valued at $181,000 after acquiring an additional 6,903 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 259.0% during the third quarter. Russell Investments Group Ltd. now owns 13,703 shares of the company’s stock valued at $162,000 after acquiring an additional 9,886 shares during the last quarter. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.